IXICO to run New Trial in Huntington’s Disease

IXICO plc, a company specialising in brain health has been awarded a contract for a third clinical trial in Huntington’s disease (‘HD’) by a new US-based drug development specialty pharmaceutical customer. The contract is for an early phase trial for a novel treatment where IXICO will be providing a battery of advanced MRI imaging techniques and clinical trial endpoints. 

This follows the announcements in May and November 2014 of contracts awarded and then extended with two top 15 pharmaceutical companies. This third contract extends and consolidates IXICO’s presence in, and revenues to be derived from, this important disease area and further expands the Company’s track record and capabilities in advanced MRI imaging techniques.  

Professor Derek Hill, Chief Executive of IXICO, commented: “This third contract in Huntington’s disease is gratifying recognition of the success of our developing specialisation in both this disease area and in advanced MRI imaging techniques.  These growth areas complement our well established position in the provision of similar support for clinical trials in Alzheimer’s disease.”